FindTrial
Sign In

N-Rephasin® SAL200

BIOLOGICAL3 trials

Sponsors

Intron Biotechnology, Inc.

Conditions

Anti-Bacterial AgentsHealthy VolunteersMethicillin-Resistant Staphylococcus AureusMethicillin-Sensitive Staphylococcus Aureus InfectionStaphylococcus Aureus Bacteremia

Phase 1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers
CompletedNCT01855048
Intron Biotechnology, Inc.Anti-Bacterial Agents, Healthy Volunteers, Methicillin-Resistant Staphylococcus Aureus
Start: 2013-08-06End: 2014-02-07Updated: 2021-11-03
A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers
CompletedNCT03446053
Intron Biotechnology, Inc.Anti-Bacterial Agents, Healthy Volunteers, Methicillin-Resistant Staphylococcus Aureus +1
Start: 2018-02-07End: 2019-02-07Updated: 2021-11-03

Phase 2

Phase IIa Clinical Study of N-Rephasin® SAL200
TerminatedNCT03089697
Intron Biotechnology, Inc.Anti-Bacterial Agents, Staphylococcus Aureus Bacteremia
Start: 2017-03-07End: 2019-11-07Updated: 2021-10-06

Related Papers

A Phase 1 Study To Evaluate Safety and Pharmacokinetics following Administration of Single and Multiple Doses of the Antistaphylococcal Lysin LSVT-1701 in Healthy Adult Subjects.
2022-01-1014 citations
Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers
Antimicrobial Agents and Chemotherapy2017-03-28173 citations